US Government acquires first 100 million doses of Pfizer, BioNTech COVID-19 vaccine candidate
The U.S. government had entered into an agreement with Pfizer and BioNTech to acquire the first 100 million doses of a potential COVID-19 vaccine.
The potential vaccine is still awaiting approval by the U.S. Food and Drug Administration (FDA). The deal includes payment of $1.95 billion by the U.S. government.
According to Pfizer, the U.S. can also acquire an additional 500 million doses of the vaccine under the current agreement. The candidate, named BNT162, is the latest in a portfolio of vaccines receiving investments from the Biomedical Advanced Research and Development Authority (BARDA).
The deal is part of the government’s “Operation Warp Speed” initiative. Get the full story from our sister publication Drug Topics.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
